

RESEARCHERS WANT TO HELP CANCER PATIENTS AND SURVIVORS EXPERIENCING CIPN WITH A NEW POTENTIAL CIPN TREATMENT

Experience the Relief from CIPN You Deserve

Chemotherapy-induced peripheral neuropathy (CIPN) affects a number of cancer patients and survivors. This painful condition causes inflammation or swelling due to nerve damage. Currently, there is no specific treatment for CIPN, but researchers are wanting to help patients in any way they can.



Researchers are exploring a potential new treatment for CIPN and are looking for volunteers to participate in a multi-site research study in Australia. This study is exploring a medication that is nearly identical to a natural protein already produced by the body when we exercise in order to help reduce inflammation. The goal of this study is to show that the study medication can provide the same relief to patients with CIPN.

Who is doing the study?

PARC is a research group lead by Professor Guy Ludbrook, conducting specialised research into multiple disciplines.

The purpose of PARC is to undertake clinical research for the pharmaceutical and biotech industries, and to provide a safe and suitable environment for the conduct of academic clinical studies. PARC has extensive experience in clinical research, including products in early phase of development that require specialised management.

PARC has extensive experience in studies that engage in a broad range of therapeutic areas, and across various development stages. The location in the Royal Adelaide Hospital and University heritage allows access to a large number of specialist clinicians, many who require a unique and flexible facility such as PARC to conduct their clinical research studies.


The PARC facility operates 24 hours a day, 7 days a week. This allows for intensive monitoring for narrow therapeutic margin (higher risk) therapies, and the non-hospital allocated beds allow for overnight and participant studies to be conducted with ease, providing greater flexibility to sponsors and clinicians.

Why participate in this study?

- Participants will receive a new potential treatment for chemotherapy-induced peripheral neuropathy at no cost.
- Participants will be reimbursed for any reasonable travel, parking, meals, and other expenses incurred with research visits.
- Participants may experience improvements in their pain caused by CIPN.
- Participants will be contributing valuable information that may benefit those suffering from CIPN in the future.
- Participants will be helping to advance medical research.

Who can participate?

- Individuals aged 18 and above who have a history of cancer or are currently in remission.
- Must be experiencing symptoms of chemotherapy-induced peripheral neuropathy for at least 3 months after completing cancer treatment.
- Must have a history of treatment with a chemotherapeutic agent.
- Must be willing and able to administer the study treatment at home (or have their caregiver administer the study treatment).
- Must be willing to use effective means of contraception throughout the duration of this study.
- Must not have a known allergy to medications such as acetaminophen (paracetamol).
- Must be able to attend 16 study visits at the research site over approximately 24 weeks.



Scan the QR Code
to Learn More

Join Now

